Abstract
Objectives: More than one in ten adults–and about one in three young adults–report past year cannabis use in Canada. While cannabis use is associated with a variety of health risks, current policy prohibits all use, rather than adopting a public health approach focusing on interventions to address specific risks and harms as do policies for alcohol. The objective of this paper was to develop ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) based on research evidence on the adverse health effects of cannabis and factors that appear to modify the risk of these harms.
Methods: Relevant English-language peer-reviewed publications on health harms of cannabis use were reviewed and LRCUG were drafted by the authors on the basis of a consensus process.
Synthesis: The review suggested that health harms related to cannabis use increase with intensity of use although the risk curve is not well characterized. These harms are associated with a number of potentially modifiable factors related to: frequency of use; early onset of use; driving after using cannabis; methods and practices of use and substance potency; and characteristics of specific populations. LRCUG recommending ways to reduce risks related to cannabis use on an individual and population level–analogous to ‘Low Risk Drinking Guidelines’ for alcohol–are presented.
Conclusions: Given the prevalence and age distribution of cannabis use in Canada, a public health approach to cannabis use is overdue. LRCUG constitute a potentially valuable tool in facilitating a reduction of health harms from cannabis use on a population level.
Résumé
Objectifs: Plus d’un adulte sur dix–et environ un jeune adulte sur trois–déclare avoir consommé du cannabis au cours de la dernière année au Canada. La consommation de cannabis est associée à divers risques pour la santé, mais contrairement aux politiques sur l’alcool, la politique actuelle sur le cannabis interdit toute consommation plutôt que d’adopter une approche de santé publique avec des interventions faites pour aborder les risques et les méfaits particuliers de cette drogue. Nous avons voulu élaborer des « directives de consommation à moindre risque pour le cannabis » (DCMRC) à la lumière des données de recherche sur les effets défavorables du cannabis pour la santé et sur les facteurs qui semblent atténuer le risque de ces méfaits.
Méthode: Nous avons examiné des publications à comité de lecture, de langue anglaise, portant sur les méfaits pour la santé de la consommation du cannabis, et rédigé des DCMRC selon un processus consensuel.
Synthèse: Notre examen a montré que les méfaits du cannabis pour la santé augmentent avec l’intensité de la consommation, mais que la courbe du risque n’est pas bien définie. Les méfaits du cannabis sont associés à des facteurs potentiellement modifiables liés à: la fréquence de consommation; le début précoce de la consommation; la conduite automobile après la consommation; les méthodes et les pratiques de consommation et la teneur de la substance; et les caractéristiques de certaines populations. Nous présentons nos DCMRC, qui recommandent des moyens de réduire les risques de la consommation de cannabis à l’échelle individuelle et populationnelle–un peu comme les « directives de consommation à faible risque » pour l’alcool.
Conclusion: Étant donné la prévalence et la structure par âge de la consommation de cannabis au Canada, une politique publique sur le cannabis conçue sous l’angle de la santé publique se fait attendre depuis longtemps. Nos DCMRC pourraient être un précieux outil pour faciliter la réduction des méfaits pour la santé de la consommation de cannabis à l’échelle de la population.
Similar content being viewed by others
References
Health Canada. Canadian Alcohol and Drug Use Monitoring Survey, 2010.
Room R, Fischer B, Hall W, Lenton S, Reuter P. Cannabis Policy: Moving Beyond Stalemate. New York, NY: Oxford University Press and The Beckley Foundation, 2010.
Dauvergne M. Trends in police-reported drug offences in Canada. Juristat 2009;29:1–25.
Room R, Babor T, Rehm J. Alcohol and public health: A review. Lancet 2005;365:519–30.
Fischer B, Rehm J, Irving H, Ialomiteanu A, Fallu J-S, Patra J. Typologies of cannabis users and associated characteristics relevant for public health: A latent class analysis of data from a nationally representative Canadian adult survey. Int J Methods Psychiatric Res 2010;19:110–24.
Angus Reid Strategies. Canadians want federal government to retain drug harm reduction programs, 2008.
Bondy SJ, Rehm J, Ashley MJ, Walsh G, Single E, Room R. Low-risk drinking guidelines: The scientific evidence. Can J Public Health 1999;90:264–70.
Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 2003;98:685–92.
Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction 2008;103:969–76.
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383–91.
Anthony J. The epidemiology of cannabis dependence. In: Roffman R, Stephens R (Eds.), Cannabis Dependence: Its Nature, Consequences and Treatment. Cambridge, UK: Cambridge University Press, 2006.
Kalant H. Adverse effects of cannabis on health: An update of the literature since 1996. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004;28:849–63.
Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005;100:354–66.
Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey MT. Mental health of teenagers who use cannabis: Results of an Australian survey. Br J Psychiatry 2002;180:216–21.
McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. Int J Drug Policy 2010;21:10–19.
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117–27.
Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 2005;24:39–48.
Patton GC, Coffey C, Lynskey MT, Reid S, Hemphill S, Carlin JB, et al. Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction 2007;102:607–15.
Kelly E, Darke S, Ross J. A review of drug use and driving: Epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004;23:319–44.
Coffey C, Carlin JB, Degenhardt L, Lynskey M, Sanci L, Patton GC. Cannabis dependence in young adults: An Australian population study. Addiction 2002;97:187–94.
Block RI, O’ Leary DS, Hichwa RD, Augustinack JC, Boles Ponto LL, Ghoneim MM, et al. Effects of frequent marijuana use on memory related regional cerebral blood flow. Pharmacology, Biochemistry & Behavior 2002;72:237–50.
Pope HG, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996;275:521–27.
Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99:1333–41.
Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand 1989;79:505–10.
Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003;33:15–21.
Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007;370:319–28.
Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997;92:279–96.
Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. J Affect Disord 2006;95:103–10.
Andreasson S, Allebeck P. Cannabis and mortality among young men: A longitudinal study of Swedish conscripts. Scand J Soc Med 1990;18:9–15.
Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary Results for 2008. Ottawa, ON: Health Canada, 2009. Available at: http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2008/summary-sommaire-eng.php (Accessed March 2, 2010).
Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications. Arch Intern Med 2007;167:221–28.
Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk: A systematic review. Alcohol 2005;35:265–75.
Swift W, Copeland J, Lenton S. Cannabis and harm reduction. Drug Alcohol Rev 2000;19:101–12.
Tashkin DP. Effects of cannabis on the respiratory system. In: Kalant H, Corrigall W, Hall W, Smart R (Eds.), The Health Effects of Cannabis. Toronto, ON: Addiction Research Foundation, 1999.
Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetra-hydrocannabinol. J Pharm Sci 2006;95:1308–17.
Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pryolytic compounds. J Cannabis Therapeutics 2004;4:7–27.
King LA, Carpentier C, Griffiths P. Cannabis potency in Europe. Addiction 2005;100:884–86.
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:488–91.
Porath-Waller AJ, Beirness DJ, Beasley EE. Toward a more parsimonious approach to drug recognition expert evaluations. Traffic Inj Prev 2009;10:513–18.
Ramaekers JG, Bergaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004;73:109–19.
Fergusson DM, Horwood LJ, Boden JM. Is driving under the influence of cannabis becoming a greater risk to driver safety than drink driving? Findings from a longitudinal study. Accid Anal Prev 2008;40:1345–50.
Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict 2009;18:185–93.
Grotenhermen F, Leson G, Berghaus G, Drummer OH, Kruger H, Longo M, et al. Developing limits for driving under cannabis. Addiction 2007;102:1910–17.
Ramaekers J, Berghaus G, van Laar M, Drummer O. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004;73:109–19.
El Marroun H, Tiemeier H, Steegers EAP, Jaddoe VWV, Hofman A, Verhulst FC, et al. Intrauterine cannabis exposure affects fetal growth trajectories: The Generation R Study. J Am Acad Child Adolesc Psychiatry 2009;48:1173–81.
Schempf AH. Illicit drug use and neonatal outcomes: A critical review. Obstet Gynecol Surv 2007;62:749–57.
Fergusson DM, Horwood LJ, Northstone K, ALSPAC Study Team. Maternal use of cannabis and pregnancy outcome. BJOG: Int J Obstetrics Gynaecol 2002;109:21–27.
Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103:2805–9.
Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003;71:37–48.
van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 2002;156:319–27.
Author information
Authors and Affiliations
Corresponding author
Additional information
Acknowledgements: The authors acknowledge research funding support from the Canadian Institute of Health Research (CIHR), the Michael Smith Foundation for Health Research (MSFHR), and the Ontario Ministry of Health and Long-Term Care for salary support for CAMH-affiliated authors. Wayne Hall is funded by an NHMRC Australia Fellowship.
Conflict of Interest: None to declare.
Rights and permissions
About this article
Cite this article
Fischer, B., Jeffries, V., Hall, W. et al. Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. Can J Public Health 102, 324–327 (2011). https://doi.org/10.1007/BF03404169
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03404169